Lead Product(s) : Copper Sulphate Pentahydrate
Therapeutic Area : Ophthalmology
Study Phase : Phase I/ Phase II
Sponsor : Glaukos
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Glaukos Licenses Iveena’s Investigational Keratoconus Therapy
Details : Under the licensing agreement with Glaukos Corporation that grants Glaukos an exclusive global license to develop and commercialize IVMED-80 (copper sulfate), a pharmacologic treatment for keratoconus.
Brand Name : IVMED-80
Molecule Type : Small molecule
Upfront Cash : $10.0 million
August 24, 2022
Lead Product(s) : Copper Sulphate Pentahydrate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I/ Phase II
Sponsor : Glaukos
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?